Literature DB >> 25234720

Interleukin 23 produced by myeloid dendritic cells contributes to T-cell dysfunction in HIV type 1 infection by inducing SOCS1 expression.

Ankita Garg1, Pratima Rawat1, Stephen A Spector2.   

Abstract

The mechanism of myeloid dendritic cell (mDC)-mediated impaired T-cell function was investigated during human immunodeficiency virus type 1 (HIV-1) infection. HIV or gp120 were found to inhibit lipopolysaccharide-induced mDC maturation and cause defects in allogeneic T-cell proliferation, interleukin 2 and interferon γ (IFN-γ) production, and phosphorylated STAT1 expression. gp120-treated mDCs downregulated autologous T-cell proliferation and IFN-γ production against a peptide pool consisting of cytomegalovirus, Epstein-Barr virus, and influenza virus (CEF). These T-cell defects were associated with a decrease in production of the T-helper type 1-polarizing cytokine interleukin 12p70 and an increase in interleukin 23 (IL-23) production by gp120-treated mDCs. gp120-induced IL-23 upregulated suppressor of cytokine signaling 1 (SOCS1) protein in T cells, which inhibited IFN-γ production and killing of CEF-pulsed monocytes. These effector functions were recovered by silencing SOCS1 in T cells. Furthermore, we observed IL-23-induced SOCS1 binding to the IFN-γ transcription complex. These results identify SOCS1 as a novel target to improve the immune function in HIV-infected persons.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV-1; IL-23; SOCS1; gp120; myeloid dendritic cells

Mesh:

Substances:

Year:  2014        PMID: 25234720      PMCID: PMC4402373          DOI: 10.1093/infdis/jiu523

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  50 in total

1.  Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells.

Authors:  A Langenkamp; M Messi; A Lanzavecchia; F Sallusto
Journal:  Nat Immunol       Date:  2000-10       Impact factor: 25.606

Review 2.  Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.

Authors:  Giuseppe Pantaleo; Richard A Koup
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

3.  SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine.

Authors:  W S Alexander; R Starr; J E Fenner; C L Scott; E Handman; N S Sprigg; J E Corbin; A L Cornish; R Darwiche; C M Owczarek; T W Kay; N A Nicola; P J Hertzog; D Metcalf; D J Hilton
Journal:  Cell       Date:  1999-09-03       Impact factor: 41.582

4.  Enhanced Th17 phenotype in uninfected neonates born from viremic HIV-1-infected pregnant women.

Authors:  Joana Hygino; Morgana M Vieira; Landi V Guillermo; Renato G Silva-Filho; Carmen Saramago; Agostinho A Lima-Silva; Regis M Andrade; Arnaldao F B Andrade; Rodrigo M Brindeiro; Amilcar Tanuri; Vander Guimarães; Cleonice Alves de Melo Bento
Journal:  J Clin Immunol       Date:  2010-12-07       Impact factor: 8.317

5.  Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load.

Authors:  H Donaghy; A Pozniak; B Gazzard; N Qazi; J Gilmour; F Gotch; S Patterson
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

6.  HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term.

Authors:  Benoît Vingert; Daniela Benati; Olivier Lambotte; Pierre de Truchis; Laurence Slama; Patricia Jeannin; Moran Galperin; Santiago Perez-Patrigeon; Faroudy Boufassa; William W Kwok; Fabrice Lemaître; Jean-François Delfraissy; Jacques Thèze; Lisa A Chakrabarti
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

Review 7.  Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans.

Authors:  Lyudmila Lyakh; Giorgio Trinchieri; Lisa Provezza; Giuseppe Carra; Franca Gerosa
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

Review 8.  Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches.

Authors:  Nancy C Connolly; Sharon A Riddler; Charles R Rinaldo
Journal:  AIDS Rev       Date:  2005 Jul-Sep       Impact factor: 2.500

9.  Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells.

Authors:  J Geginat; F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

10.  Regulation of interferon gamma signaling by suppressors of cytokine signaling and regulatory T cells.

Authors:  Joseph Larkin; Chulbul M Ahmed; Tenisha D Wilson; Howard M Johnson
Journal:  Front Immunol       Date:  2013-12-18       Impact factor: 7.561

View more
  4 in total

1.  Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4.

Authors:  Ankita Garg; Rodney Trout; Stephen A Spector
Journal:  Sci Rep       Date:  2017-03-24       Impact factor: 4.379

Review 2.  Immunoregulatory Functions of the IL-12 Family of Cytokines in Antiviral Systems.

Authors:  Yifei Guo; Wei Cao; Ying Zhu
Journal:  Viruses       Date:  2019-08-22       Impact factor: 5.048

Review 3.  Cytokines and microRNAs in SARS-CoV-2: What do we know?

Authors:  Fahimeh Zamani Rarani; Bahman Rashidi; Mohammad Hassan Jafari Najaf Abadi; Michael R Hamblin; Seyed Mohammad Reza Hashemian; Hamed Mirzaei
Journal:  Mol Ther Nucleic Acids       Date:  2022-06-25       Impact factor: 10.183

4.  Nonpathogenic SIV and Pathogenic HIV Infections Associate with Disparate Innate Cytokine Signatures in Response to Mycobacterium bovis BCG.

Authors:  Melanie A Gasper; Shameek P Biswas; Bridget S Fisher; Stephanie C Ehnert; David R Sherman; Donald L Sodora
Journal:  PLoS One       Date:  2016-08-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.